Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Loriot

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
ESMO Open|May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapyA Bamias, A S Merseburger, Y Loriot, et al.
Cancer Chemotherapy and Pharmacology|June 24, 2023
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patientsM Valery, K Saleh, R Ecea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 studyA Necchi, R W Joseph, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abirateroneC Massard, J Mateo, Y Loriot, et al.
Cell Death & Disease|September 19, 2014
Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancerY Loriot, P Mordant, D Dugue, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upT Powles, J Bellmunt, E Comperat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2023
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinomaJ E Rosenberg, T Powles, G P Sonpavde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 15, 2024
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinomaT Powles, J Bellmunt, E Comperat, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]C Dariane, C Pasqualini, N Gaspar, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 7, 2022
[Guidelines from the cancer (CC-AFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG]F Audenet, A Sotto, M Roumiguié, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
ESMO Open|May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapyA Bamias, A S Merseburger, Y Loriot, et al.
Cancer Chemotherapy and Pharmacology|June 24, 2023
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patientsM Valery, K Saleh, R Ecea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 studyA Necchi, R W Joseph, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abirateroneC Massard, J Mateo, Y Loriot, et al.
Cell Death & Disease|September 19, 2014
Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancerY Loriot, P Mordant, D Dugue, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upT Powles, J Bellmunt, E Comperat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2023
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinomaJ E Rosenberg, T Powles, G P Sonpavde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 15, 2024
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinomaT Powles, J Bellmunt, E Comperat, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]C Dariane, C Pasqualini, N Gaspar, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 7, 2022
[Guidelines from the cancer (CC-AFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG]F Audenet, A Sotto, M Roumiguié, et al.
Pageof 8